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The D0 Domain of KIR3D Acts as a Major Histocompatibility Complex Class I
Binding Enhancer
Abstract
In contrast to the KIR2D:HLA-C interaction, little is known of KIR3DL1's interaction with HLA-B or the role
of D0, the domain not present in KIR2D. Differences in the strength and specificity for major
histocompatibility complex class I of KIR3DL1 and its common chimpanzee homologue Pt-KIR3DL1/2
were exploited to address these questions. Domain-swap, deletion, and site-directed mutants of KIR3DL1
were analyzed for HLA-B binding using a novel, positively signaling cell–cell binding assay. Natural
‘deletion’ of residues 50 and 51 from its D0 domain causes Pt-KIR3DL1/2 to bind Bw4+ HLA-B allotypes
more avidly than does KIR3DL1. Deletion of these residues from KIR3DL1, or their substitution for alanine,
enhanced binding of Bw4+ HLA-B. None of 15 different point mutations in D0 abrogated KIR3DL1 binding
to Bw4+ HLA-B. In contrast point mutations in the D1 and D2 domains of KIR3DL1, made from knowledge
of KIR2D:HLA-C interactions, disrupted binding to Bw4+ HLA-B. The results are consistent with a model in
which D1 and D2 make the principal contacts between KIR3DL1 and HLA-B while D0 acts through a
different mechanism to enhance the interaction. This modulatory role for D0 is compatible with natural
loss of expression of the D0 domain, a repeated event in the evolution of functional KIR genes.
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Salim I. Khakoo, Ron Geller, Sunny Shin, Jomaquai A. Jenkins,
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Department of Structural Biology, and Department of Microbiology and Immunology, Stanford University School of
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Introduction
NK cells are key players in the innate immune response to
pathogens (1). Their functions are controlled by multiple
inhibitory and activating cell surface receptors (2, 3). A particular diverse family of NK cell receptors is the killer cell
Ig-like receptors (KIR).* KIR have either two (KIR2D) or
three (KIR3D) extracellular immunoglobulin domains and
either short (S) or long (L) intracytoplasmic tails which
S.I. Khakoo’s present address is Academic Medicine, Mailpoint 811,
Level D South Block, Southampton General Hospital, Tremona Rd.,
Southampton, Hants., SO16 6YD, UK.
Address correspondence to Dr. Peter Parham, Department of Structural Biology, Sherman Fairchild Building, 299 Campus Dr. West, Stanford University School of Medicine, Stanford, CA 94305-5126. Phone:
650-723-7456; Fax: 650-723-8464; E-mail: peropa@leland.stanford.edu
*Abbreviations used in this paper: AP, alkaline phosphatase; KIR, killer
cell immunoglobulin-like receptor; KIR2D, killer cell immunoglobulin-like receptor with two Ig-like domains; KIR2DS, killer cell immunoglobulin-like receptor with two Ig-like domains and short cytoplasmic
tail; KIR2DL, killer cell immunoglobulin-like receptor with two Ig-like
domains and long cytoplasmic tail; KIR3D, killer cell immunoglobulinlike receptor with three Ig-like domains; KIR3DL, killer cell immunoglobulin-like receptor with three Ig-like domains and long cytoplasmic
tail; SEAP, secretion of alkaline phosphatase.
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transduce positive and negative signals, respectively (4–7).
Within an individual, NK cells are distinguished by their
stable expression of different combinations of KIR, which
creates a diverse NK cell repertoire (8). The known ligands
for KIR are all MHC class I molecules: HLA-C is recognized by KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS1,
and KIR2DS2 (9–11); HLA-B is recognized by KIR3DL1
(12, 13), and HLA-A is recognized by KIR3DL2 (14, 15),
and HLA-G is recognized by KIR2DL4 (16). As both KIR
and MHC class I are diverse and evolve rapidly, their functional binding relationships must be constantly challenged,
through independent segregation of the two gene families
in populations and by the production of new variants
through recombination and mutation.
X-ray crystallographic analysis of complexes has given
high-resolution images of KIR2DL2 bound to HLA-Cw3
and of KIR2DL1 bound to HLA-Cw4 (17, 18). In both
complexes loops from the D1 and D2 domains of KIR2D
bind with approximately orthogonal orientation across the
COOH-terminal part of the 1 helix and the NH2-terminal part of the 2 helix. The ligand–receptor interaction is
dominated by charge complementarity with HLA-C speci-
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In contrast to the KIR2D:HLA-C interaction, little is known of KIR3DL1’s interaction with
HLA-B or the role of D0, the domain not present in KIR2D. Differences in the strength and
specificity for major histocompatibility complex class I of KIR3DL1 and its common chimpanzee homologue Pt-KIR3DL1/2 were exploited to address these questions. Domain-swap, deletion, and site-directed mutants of KIR3DL1 were analyzed for HLA-B binding using a
novel, positively signaling cell–cell binding assay. Natural ‘deletion’ of residues 50 and 51 from
its D0 domain causes Pt-KIR3DL1/2 to bind Bw4 HLA-B allotypes more avidly than does
KIR3DL1. Deletion of these residues from KIR3DL1, or their substitution for alanine, enhanced binding of Bw4 HLA-B. None of 15 different point mutations in D0 abrogated
KIR3DL1 binding to Bw4 HLA-B. In contrast point mutations in the D1 and D2 domains of
KIR3DL1, made from knowledge of KIR2D:HLA-C interactions, disrupted binding to Bw4
HLA-B. The results are consistent with a model in which D1 and D2 make the principal contacts between KIR3DL1 and HLA-B while D0 acts through a different mechanism to enhance
the interaction. This modulatory role for D0 is compatible with natural loss of expression of the
D0 domain, a repeated event in the evolution of functional KIR genes.
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Materials and Methods
Recombination PCR for KIR-CD3 Chimeric Molecules. KIRCD3 chimeric molecules were generated by recombination
PCR (25). In these molecules the extracellular and transmembrane domains of the KIR are attached to the intracellular
domain of CD3  . Pt-KIR3DL1/2 was amplified from an
error-free clone (M1.1–3-10) using sense primer 5-1ATG-
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TTGCTCATGGTCGTCAGCATGGCGTGTGTTGGGTTCTTCTTGCTGCA-3 and antisense primer 5-TGCGCTCCTGCTGAA1126TTTGTTGGAGCACCAGCGATGAAG-3.
As the clone from which the Pt-KIR3DL1/2 gene was amplified
did not contain the full leader sequence, the leader sequence of
KIR3DL1*002 (NKB1 [4]) was included in the sense primer (underlined) to ensure cell surface expression of the mature protein.
The antisense primer contained 15 bp of CD3 at the 5 end (underlined) to allow annealing to the CD3 sequence during the
subsequent recombination PCR step. PCR conditions were: denaturation at 95C for 2 min, followed by 15 cycles of 45 s at
60C, 60 s at 72C, 30 s at 95C, then 7 min at 72C. CD3 was
amplified from a CD3-containing plasmid (25) using the sense
primer 5-TGGTGCTCCAACAAA237TTCAGCAGGAGCGCAGAGCC-3 which contains 15 bp of Pt-KIR3DL1/2 at the
5 end (underlined) and antisense primer 5-822CGAGGAACCGCCAGGAGACA-3 under the same PCR conditions.
The KIR and CD3 were recombined in a PCR reaction using
the Pt-KIR3DL1/2 and CD3 amplification products as templates and the following primers; sense 5-GGGCGCGGCCGC6AGCAGTATGTTGCTCATGGTCGTCAGC-3 (N1fnot) antisense 5-GGGCTCTAGA599TGGCCTTTGAGTGGTGAAATCC-3, (zeta3xba) which incorporate the restriction
sites NotI and Xba1 (underlined), respectively. PCR conditions
were: denaturation at 95C for 2 min, followed by 15 cycles of
45 s at 60C, 90 s at 72C, 30 s at 95C, then 7 min at 72C. The
amplification product was cloned into pcDEF and sequenced to
ensure fidelity.
An error-free clone was transfected into the Jurkat cell line by
electroporation using a BTX electroporator with two pulses of
240 V at 100 F and resistance 360 ohms. Transfectants were selected with G418 (Sigma-Aldrich) at a concentration of 2 mg/
ml. After selection, cells expressing Pt-KIR3DL1/2-CD3 chimeric molecules were stained with the DX9 antibody, sorted,
and cultured.
The KIR3DL1-CD3 construct was made in the same way as
Pt-KIR3DL1/2-CD3 using the KIR3DL1*002-containing plasmid LL349 (4) as template, except that the primers for the first
amplification were 5-16CGGCACCGGCAGCACCATGT-3
(which sits in the 5 untranslated region of KIR3DL1*002), and
5-TGCGCTCCTGCTGAA1126TTTGTTGGAGCACCAGAGATGAAG-3, which includes 15 bp of the CD3 gene (underlined) at the 5 end and amplifies the same region of the transmembrane and intracytoplasmic region as the corresponding
primer for Pt-KIR3DL1/2. PCR conditions were the same as for
Pt-KIR3DL1/2. The resulting stable transfectants were sorted by
flow cytometry for high KIR expression using either the DX9 (a
gift from Dr. L. Lanier, San Francisco, CA) or Z27 (Beckman
Coulter) anti-KIR3DL1 monoclonal antibodies. Cultured transfectants were periodically checked for both KIR and CD3 expression.
Assay of Secreted Alkaline Phosphatase. 1
107 Jurkat-KIR
transfectants were transfected with the alkaline phosphatase (AP)
reporter construct NFAT-SX (10 g) and an SV40 TAg (0.5 g)
expression construct driven by an RSV promoter (26). NFAT-SX
contains sequences encoding an NFAT binding site and a minimal IL-2 promoter cloned upstream of a cDNA encoding secreted AP (27). The SV40 TAg construct was used to increase the
copy number of the reporter construct.
24 h after transfection of the reporter construct, cells were
plated out at 106 cells per ml at a 2.5:1 ratio with stimulator cells,
in a final volume of 200 l. Incubation was for 18 h. Endogenous
AP was heat inactivated at 67C for 2 h and then 100 l aliquots
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ficity being determined by the residue at position 44, as was
first shown in binding experiments (19).
In comparison to the interactions of KIR2D with HLA-C,
little is known of the interaction between KIR3D and
either HLA-B or HLA-A. On the basis of sequence comparison and modeling it was proposed that the D1 and D2
domains of KIR3D interact with MHC class I in a homologous manner to the KIR2D:HLA-C interaction (20).
However this model neither explains the presence of the
D0 domain nor does it account for the results of Rojo et al.
demonstrating that all three of the Ig domains of KIR3DL1
are required for binding to HLA-B (21).
The KIR2D genes encoding HLA-C receptors form part
of a larger group of KIR called lineage III KIR (22). Genomic analysis revealed that all KIR2D genes of lineage III
contain a pseudoexon encoding a D0 domain that is not
incorporated into mature RNA (23, 24). Thus, all the
genes encoding these KIR2D have evolved from genes encoding KIR3D. Inactivation of the D0 domain appears to
have happened on several occasions as the inactivating
mechanism differs among KIR2D genes. The extent to
which the D0 domains of lineage III KIR are inactivated
varies between species. For example, in common chimpanzees it is uncommon, in comparison to humans, and in that
species one MHC-C receptor is a KIR3D and the other a
KIR2D (22). Thus, during the evolution of lineage III
KIR there seem to have been circumstances when having a
D0 domain was of benefit and others when it was better
got rid of.
Human KIR specific for HLA-A and B form part of another KIR lineage, lineage II, which is comprised solely of
KIR3D. Whereas in humans this lineage is represented by
two genes, KIR3DL1 and KIR3DL2, in the common
chimpanzee there is a single gene, for which the common
allele, Pt-KIR3DL1/2, combines structural elements
and functional properties of both human genes with
some unique features. Thus, Pt-KIR3DL1/2 combines an
MHC-B specificity, which is overlapping but distinct from
KIR3DL1, with a weak specificity for some MHC-A allotypes akin to that of KIR3DL2. In cytotoxicity assays PtKIR3DL1/2 appeared a more avid MHC class I receptor
than either KIR3DL1 or KIR3DL2 (22). Because of these
differences further comparison of HLA-B recognition by
KIR3DL1 and Pt-KIR3DL1/2, provided a system that facilitated the investigation described here of the D0 domain’s function. We find that D0 enhances functional interaction with Bw4 HLA-B ligand, with the chimpanzee
D0 domain being a stronger enhancer than its human
counterpart.
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as described by Gumperz et al. (13). After digestion with BamHI
and ApaI the resulting fragment was subcloned into pBluescript.
Mutagenesis was performed as described above for KIR. Plasmids containing the relevant mutations were cloned back into
pcDNA-B*3801 using BamHI and ApaI. The resulting constructs were checked by sequence analysis and clones corresponding to the designed mutants transfected into 721.221 as
described previously (28).
NK Cell Clones and Cell Killing Assays. Procedures were as
described previously (22). NK cell clones chosen for analysis lysed
untransfected 721.221 cells at levels 30% specific lysis.
B Cell Lines and 721.221 Transfectants. EBV transformed
lymphoblastoid B cell lines were: YAR (HLA-A*2601, -B*3801,
-C*1203), Blair (Patr-A*0401, -A*1101, -B*0101, -B*1301,
-C*0301, -C*0401), Chatter (Patr-A*0101, -A*0404, -B*0501,
-B*1602, -C*0501, -C*0601), Ross (Patr-A*0401, -A*1401,
-B*1601, -B*1701, -C*0301, -C*0401), and Todd (Patr-A*0402,
-A*0601, -B*1701, -B*2001, -C*0601, -C*1201). 721.221 transfectants expressing individual HLA class I alleles were generated as
described previously (28), except for that expressing HLAB*3801, which had been cloned into pcDNA3.1 in order to perform mutagenesis.

Results
A Novel Cellular Assay that Detects KIR3D Binding to
MHC Class I. Analysis of functional MHC class I interactions with KIR has largely relied upon detecting lack of lysis in cellular cytotoxicity assays. Because of the inherent
limitations in measuring this negative effect, we developed
a cellular assay which detects KIR3D binding to HLA-B
with positive read-out. Constructs were made that encoded
chimeric receptors containing the extracellular domains of
KIR3DL1 or Pt-KIR3DL1/2 fused to the intracytoplasmic
domain of CD3. In these constructs the ligand recognition
part of each KIR is retained but the negatively signaling
cytoplasmic region is replaced by the corresponding, positively signaling, region of CD3. Stable transfectants of Jurkat cells expressing chimeric KIR3D constructs were then
transiently transfected before each assay with the NFATSX reporter construct in which the AP gene is driven by an
NFAT-binding promoter (26). In the assay Jurkat double
transfectants expressing KIR3D and NFAT-SX are incubated with B lymphoblastoid cells expressing MHC class I.
Binding of KIR3D on the Jurkat cells to MHC class I on
the stimulator cells leads to secretion of AP which is quantified in the extracellular medium (27). For short this assay
is called the SEAP assay, for secretion of AP.
Our analysis aimed first to compare results from the
SEAP assay with those obtained from measurements of inhibition in conventional cellular cytotoxicity assays. Class
I–deficient 721.221 B cells stimulated little response from
Pt-KIR3DL1/2 or KIR3DL1 in the SEAP assay,
whereas B cell lines expressing a normal complement of
MHC-A, B, and C molecules stimulated a range of response (Fig. 1). Inclusion of the anti–MHC class I monoclonal antibody W6/32 in the assay abrogated the response,
demonstrating its dependence upon MHC class I. Dependence upon expression of a KIR3D construct was shown
in assays performed with Jurkat cells transfected with the pc-
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of the cell supernatants harvested. 100 l of 2 M diethanolamine
containing 1 M methylumbelliferyl phosphate and 10 mM l-homoarginine were added to the supernatants and the mixture incubated overnight at 37C. Fluorescence was measured in a Titertek
Fluorescan II (Labsystems) at 355 nm excitation and 460 emission. AP activity was expressed as a percentage of stimulation by
plate-bound anti-CD3 alone; with the baseline reading to calibrate the fluorometer at zero being from wells with “medium
alone.” All experiments were done in duplicate and performed at
least three times. Anti-CD3 stimulation was usually between 600
and 1,200 fluorescence units. Results are expressed as the mean
plus one SEM from all experiments performed with each transfectant. In blocking experiments the anti–class I antibody W6/32,
or an isotype-matched control antibody, were added to give a final concentration of 10 g/ml.
Domain Swap KIR3DL Constructs. The domain exchange
constructs were made using the pcDEF/KIR3DL1 or pcDEF/PtKIR3DL1/2 constructs as PCR templates to amplify sequences
encoding individual domains, which were then recombined by
recombination PCR. Sequences encoding D0 domains were
amplified using the primers sense N1fnot and antisense 5349TGATCACCACGGGGTTGCTGG-3. Sequences encoding
D1D2 were amplified using sense primer 5-215CGGGGTTCACACCCACACTCC-3 and antisense primer zeta3xba.
The sequence encoding the D0 domain of KIR3DL1*002 was
then recombined with that encoding the D1D2 domains of PtKIR3DL1/2 by PCR using primers N1fnot and zeta3xba to generate a chimeric gene, HCC. The resulting product was then
cloned into pcDEF using NotI and XbaI. The CHH chimera was
generated in the complementary manner.
To generate chimeric molecules in which the D2 domain was
substituted, sequences encoding the D2 domain from KIR3DL1
and Pt-KIR3DL1/2 were amplified with the CD3 gene using
sense primer 5-505CCTACAGATGCTACGGTTCTG-3 and
antisense primer zeta3xba. Sequences encoding the corresponding
D0D1 domains were amplified using the sense primer N1fnot
and the antisense primer 5-565GGGATCACTGGGAGCTGACAA-3. The appropriate amplification products were then recombined by PCR and cloned into pcDEF to generate the HHC
and CCH chimeras.
To generate chimeras in which the D1 domain was exchanged, HHC and CCH templates and primers 5505CCTACAGATGCTACGGTTCTG-3 and zeta3xba were
used to amplify sequences encoding the D1D2 domains. The resulting products were recombined with sequences encoding the
appropriate D0 and cloned into pcDEF.
PCR conditions were identical for all procedures: denaturation
at 95C for 2 min, followed by 20 cycles of 45 s at 60C, 2 min at
68C, 30 s at 95C, then 7 min at 68C. All chimeric constructs
were sequenced on a 373A automated sequencer (Applied Biosystems) to ensure fidelity.
Mutagenesis. To make KIR3DL1 mutants, a fragment was
isolated from the pcDEF/KIR3DL1 construct using the restriction enzymes NotI and NdeI and subcloned into pGEM. Mutagenesis was performed in this vector using the Quick Change™
mutagenesis kit (Stratagene) and oligonucleotide primers containing the relevant mutations, per manufacturer’s protocol. The fidelity of the procedures was checked by sequencing. The product
from a plasmid containing the relevant mutation was cloned back
into pcDEF using the NotI and NdeI restriction enzymes. The
resulting constructs were again checked by sequence analysis.
To make HLA-B*3801 mutants, the complete coding sequence of HLA-B*3801 was cloned into pcDNA3.1 (Invitrogen)
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DEF vector alone (Fig. 1). Whereas chimpanzee PtKIR3DL1/2 responded to both human and chimpanzee
B cells lines human KIR3DL1 responded only to the human cell line. This differential was previously observed in
cytotoxicity assays in which HLA class I were good inhibitory ligands for NK cells expressing either KIR3DL1 or PtKIR3DL1/2, whereas chimpanzee Patr class I were inhibitors of NK cells expressing Pt-KIR3DL1/2 but not of cells
expressing KIR3DL1 (22).
In cytotoxicity assays KIR3DL1 and Pt-KIR3DL1/2
have different patterns of inhibition by HLA-B allotypes. A
diagnostic difference is that KIR3DL1 only engages HLA-B
allotypes having a Bw4 motif at residues 77–83 (13) whereas
Pt-KIR3DL1/2 also engages the HLA-B*1502 allotype that
has the alternative Bw6 motif (Fig. 2 A). In addition, PtKIR3DL1/2 has weak reactivity with certain MHC-A allotypes and for both receptors there is a range of response to
different MHC-B allotypes having a Bw4 motif (22).
To assess and compare the MHC class I reactivity of
KIR3DL1 and Pt-KIR3DL1/2 expressed on Jurkat cells,
914
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Figure 2. Pt-KIR3DL1/2 and KIR3DL1 exhibit similar HLA-B specificity in cytotoxicity and SEAP assays. (A) Chimpanzee NK cell clones
that express Pt-KIR3DL1/2 (1.9, 1.19, 1.27, and 1.66) kill class I–deficient cells 721.221, but not 721.221 transfectants expressing either Bw6
HLA-B*1502 or Bw4HLA-B*1513. In contrast, the human NK cell
clone PP5.3 expressing KIR3DL1 efficiently kills 721.221 cells and the
transfectant expressing HLA-B*1502 but not the transfectant expressing
HLA-B*1513. Cytolytic assays were performed at an effector to target ratio of 6:1. (B) Jurkat cells transfected with Pt-KIR3DL1/2, KIR3DL1,
or vector alone were challenged with 721.221 cells and a panel of
721.221 transfectant expressing single human or chimpanzee MHC class I
allotypes in SEAP assay. MHC class I allotypes with a Bw4 motif are depicted with bars shaded light gray, those with a Bw6 motif are depicted
with hatched bars, and those with neither motif are depicted with black
bars. The allotype Patr-B*1601, which has a mixed Bw4/Bw6 motif, is
depicted with bars shaded dark gray. Results shown are the means and
standard errors of three independent experiments.

they were challenged with a panel of 721.221 transfectants
expressing single human or chimpanzee MHC class I allotypes. Both KIR3DL1 and Pt-KIR3DL1/2 secreted AP
in a manner that was dependent upon MHC class I polymorphism but with different specificity (Fig. 2 B).
KIR3DL1 was stimulated by a subset of Bw4 HLA-B allotypes and within this group there was a gradation of response: B*3801 B*5801  B*2702 B*1513  B*2705.
Pt-KIR3DL1/2 was stimulated by a slightly different
subset of Bw4 HLA-B allotypes: B*3801  B*5801 
B*2705 B*1513 B*2702, and also by the Bw6 HLAB*1502 and by Patr-A*0402. Notable were the weak responses of Pt-KIR3DL1/2 and KIR3DL1 to transfec-
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Figure 1. Binding of MHC class I ligands to Pt-KIR3DL1/2 and
KIR3DL1 stimulates secretion of AP by Jurkat cells. Jurkat cells stably
transfected with Pt-KIR3DL1/2, KIR3DL1 or the pcDEF expression
vector alone were transiently transfected with the NFAT-SX plasmid and
then incubated with human (YAR) or chimpanzee (BLAIR, CHATTER,
ROSS, and TODD) B cell lines, or the class I–deficient B cell line
721.221. Secreted AP was quantified and normalized to the release stimulated by plate-bound anti-CD3 antibody. Assays were performed either in
the presence of the anti-MHC class I antibody W6/32 (white bars) or the
control, isotype-matched antibody CVC-7 (black bars). Results shown
are the means and standard errors of three independent experiments.
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Figure 3. The D0 domain of Pt-KIR3DL1/2 stabilizes
the interaction with MHC-B. Domain swap constructs of
KIR3DL1 and Pt-KIR3DL1 were tested against a panel
of 721.221 transfectants expressing various HLA-B allotypes in SEAP assays. The Ig domain composition of the
three constructs tested are shown. Human Ig domains are
indicated with stippled boxes and chimpanzee Ig domains
with filled boxes. The reactivities of the constructs in the
SEAP assays are shown in comparison to stimulation with
plate bound anti-CD3. The means and standard errors of
three independent experiments are shown.

swapped, and HCH in which the D1 domain of
KIR3DL1 was replaced with that of Pt-KIR3DL1/2 (Fig.
3). Mutant CHH, in which chimpanzee D0 replaces human D0, exhibited stronger reactions with all three Bw4
HLA-B allotypes tested, but no reactivity with the Bw6
HLA-B*1502. The reciprocal mutant, in which human D0
is associated with chimpanzee D1 and D2, gave a pattern of
reactivity B*3801
B*5801
B*1513, comparable to
that of KIR3DL1 and lacking reaction with B*1502.
Thus, for Pt-KIR3DL1/2, reactivity with Bw6 B*1502,
but not Bw4 HLA-B, is dependent upon the D0 domain
and upon features that distinguish the chimpanzee D0 domain from its human counterpart. The reactivity of mutant
HCH was B*3801 B*5801  B*1513  B*1502, a pattern distinct from that of KIR3DL1 and which includes the
Bw6 allotype B*1502. This suggests that substitutions in
the chimpanzee D1 domain also contribute to the recognition of HLA-B*1502.
Features unique to the D0 domain of Pt-KIR3DL1/2
are deletion of what are residues 50 and 51 in KIR3DL1
(Fig. 4) and substitution of proline for serine at position 14.
To determine the contribution these differences make to
the enhanced binding due to the Pt-KIR3DL1/2 D0 do-

Figure 4. Comparison of the
amino acid sequences of
KIR3DL1*002, Pt-KIR3DL1/2,
and KIR3DL2*001. The sequences were aligned using the
Wisconsin package version 10.1
(Genetics Computer Group).
Positions identical to the consensus sequence are indicated by
dashes (-). Residues deleted in
comparison to the consensus sequence are indicated by dots (.).
Residues indicated with the
symbol “” were mutated to
generate
the
panel
of
KIR3DL1 mutants.
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tants expressing chimpanzee MHC class I molecules. From
these results we see that the MHC class I specificities of
KIR3DL1 and Pt-KIR3DL1/2 as assessed by SEAP assay
and inhibition of cytotoxicity are similar but not identical.
The differences may be due to lower sensitivity of the SEAP
assay, such that the weaker reactions detected by inhibition
of cytotoxicity drop out, or by the absence on Jurkat T cell
transfectants of additional NK cell receptors and coreceptors
that lead to the additional reactions seen in cytotoxicity assays. Common to both assays is that chimpanzee Patr class I
molecules are generally weaker ligands for human and chimpanzee KIR3DL than human HLA class I molecules.
Natural Variation in the D0 Domain Modulates Binding to
Bw4 HLA-B Allotypes. To assess the contribution of individual Ig-like domains to differences in HLA-B recognition by KIR3DL1 and Pt-KIR3DL1/2, we made six constructs from KIR3DL1 and Pt-KIR3DL1/2 in which the
sequences encoding individual human and chimpanzee domains were recombined in all possible combinations. Of
these, three failed to give a detectable cell-surface protein
upon transfection into Jurkat cells. The three expressed recombinant mutants analyzed for HLA-B binding consisted
of HCC and CHH in which the D0 domains were
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Figure 5. Naturally occurring variations in D0 stabilize the KIR-MHC
class I interaction. (A) Comparison between the HLA-B specificities of
KIR3DL1, Pt-KIR3DL1/2, and KIR3DL1- 50,51,P14S in the
SEAP assay. Jurkat transfectants stably expressing these molecules were incubated with 721.221 transfectants expressing HLA-B*3801, B*1513,
B*1502, and B*5801, or untransfected 721.221 cells. In B a further comparison is made with KIR3DL1, Pt-KIR3DL1/2, and KIR3DL150,51 in the SEAP assay against the same panel of cell lines. The data
shown are the means and standard errors of three independent experiments in comparison to plate-bound anti-CD3.
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HLA-B*3801. Although some of the mutant KIR3DL1
molecules gave lower reactivities than the wild-type, these
differences were small and scattered in comparison to the
enhanced binding observed for mutants having alanine at
positions 49, 50, 51, or 52 (Fig. 6). The peak of this enhancement was for alanine substitutions at positions 50 and
51. Thus reduction in side-chain size as well as deletion at
residues 50 and 51 has an enhancing effect. For those
mutants giving enhanced response to HLA-B*3801 and
B*1513 there was also increased reactivity with B*1502 and
untransfected 721.221 cells (Fig. 6). These reactivities were
unaffected by addition of the HLA class I–specific antibody
W6/32 showing they are not dependent on KIR interaction with MHC class I (data not depicted). It is possible
that these mutations increase aggregation of KIR3DL1 in
the Jurkat cell membrane, which leads to an increased basal
level of AP secretion.
The interactions of three KIR3DL1 mutants having
changes at residues 50 and/or 51 in D0 with four point
mutants of HLA-B*3801 were assessed (Fig. 7). Three of
the B*3801 mutants: T73A, Y74A, and E76A, were designed to study the influence on KIR binding of HLA-B
residues in the 1 helix but outside the Bw4 motif; of these

Figure 6. Mutation at residues 49–52 in the D0 domain enhance binding of KIR3DL1 to Bw4 HLA-B. A panel of Jurkat transfectant expressing KIR3DL1 mutants having point substitutions in the D0 domain
were challenged with 721.221 transfectants expressing HLA-B*3801,
B*1513, and B*1502, as well as untransfected 721.221 cells, in SEAP assays.
The means and standard errors of three independent experiments in comparison to plate-bound anti-CD3 are shown.
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main, a mutant KIR3DL1 was made that lacks residues 50
and 51 and has serine substituted for proline at position 14.
This 50,51,P14S mutant gave a pattern of HLA-B response like that of CHH, in that there was enhanced reactivity with the Bw4 HLA-B allotypes but no reactivity
with HLA-B*1502 (Fig. 5 A). Thus, the enhanced response
appears specific for allotypes reactive with the wild-type
KIR3DL1 molecule. A mutant having just deletion of residues 50 and 51 ( 50,51) was then made and shown to
have the same binding phenotype as 50,51,P14S (Fig. 5
B). These results demonstrate that absence of residues 50
and 51 is responsible for the enhanced binding of Bw4
HLA-B by Pt-KIR3DL1/2 compared with KIR3DL1.
To investigate further the binding of the D0 domain to
MHC class I we examined the properties of KIR3DL1
mutants in which individual residues of the D0 domain, including positions 50 and 51, were substituted for alanine.
Residues were chosen for mutagenesis using the criterion
of being shared by KIR3DL1 and Pt-KIR3DL1/2 but absent from any D0 domain of a lineage I or III KIR. All 15
of the D0 mutants tested gave positive reactions with
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of tyrosine for phenylalanine converted KIR2DS2 from
null-binding phenotype to C1 binding phenotype; mutant
S140F replicates this change in KIR3DL1. At position 141
KIR3DL1, KIR3DL2 and Pt-KIR3DL1/2 all differ; mutant K141Q introduces the glutamine characteristic of PtKIR3DL1/2 into KIR3DL1. Mutations M128A in D1 and
Q256A in D2 were designed as negative controls, chosen
because their equivalents in KIR2DL2 (positions 33 and
161, respectively) do not contribute to the interaction seen
with HLA-Cw3 in the crystallographic structure of the
complex (17). The Y200A mutant bound the Z27 antibody but not the DX9 antibody, the first observation to
distinguish the reactivities of the two monoclonal antibodies and showing that tyrosine 200 of the D2 domain is an
important determinant of DX9 binding.
As anticipated the nine mutations in the D1 and D2 domains exhibited a range of response in the cell-binding assay (Fig. 8). Binding reactions were preserved in the two
negative controls mutations (M128A and Q256A) as well
as in the mutations at positions 140 and 141 (S140F and
K141Q). Mutation at positions 200 (Y200A) and 230
(D230H) caused abrogation of HLA class I binding, as seen

Figure 7. Complementary mutation in HLA-B*3801 and the D0 domain
of KIR3DL1 can stabilize ligand-receptor interaction. Jurkat transfectants
expressing KIR3DL1, Pt-KIR3DL1/2, or KIR3DL1 with substitutions
in D0 were challenged with 721.221 transfectants expressing wild-type and
mutated HLA-B*3801 molecules. The mean and standard errors of three
independent experiments are expressed as a percentage of the SEAP release
in comparison to the wild-type HLA-B*3801 transfectant.

Figure 8. Point mutations in the D1 and D2 domain abrogate binding
of KIR3DL1 to HLA-B. A panel of Jurkat transfectants each expressing a
KIR3DL1 mutant with a point substitution in the D1 and D2 domains
were challenged with 721.221 transfectants expressing HLA-B*3801,
B*1513, B*1502, and B*5801, as well as untransfected 721.221 cells in
SEAP assays. The means and standard errors from three independent experiments are shown.
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E76 is highly conserved among Bw4 and Bw6 MHC-B
allotypes. The fourth mutation, substitution of alanine for
glutamate at position 46, was predicted to have no affect on
KIR3D binding and this mutant (E46A) was designed as a
negative control. For mutants E46A, T73A, and Y74A, the
interactions with KIR3D were indistinguishable from
wild-type B*3801. The fourth B*3801 mutant, E76A, was
weakly recognized by KIR3DL1, a diminution that was
less severe for KIR3DL1 mutants having alanine at residue 50 or 51. Intermediate responses were seen for PtKIR3DL1/2 and the KIR3DL1 mutant having residues
50 and 51 deleted and proline 14 replaced by serine. Thus,
from this test system we see that changes in the D0 domain
of KIR3DL1 can compensate for reductions in KIR binding caused by substitutions in HLA-B, an illustration of
how KIR3D and MHC-B might coevolve to preserve
ligand–receptor interaction.
Mutations in the D1 and D2 Domains Reduce KIR3DL1
Interaction with HLA-B. Because none of the point mutations in the KIR3DL1 D0 domain diminished binding of
HLA-B it was important to investigate whether mutations
having such an effect could be introduced into KIR3DL1.
To do this we characterized nine KIR3DL1 mutants with
point substitutions in either the D1 domain (four mutants)
or the D2 domain (five mutants). Mutants were chosen on
the basis of different criteria with the overall aim of giving
some that would diminish binding to KIR3DL1 and others
that would not. Four mutations made in the D2 domain
(Y200A, E201A, D230H, and H278A) correspond to mutations previously characterized for KIR2DL2 (Y105A,
E106A, D135H, and D183A, respectively) and shown to
disrupt its binding to HLA-Cw3 (17). Position 139 in the
D1 domain of KIR3DL1 is the equivalent of KIR2DL1
position 44, at which substitution determines specificity for
either the C1 (lysine) or C2 (methionine) group of allotypes (19). In mutation I139K the isoleucine present in
KIR3D is replaced by lysine. Position 140 is equivalent to
position 45 at which Winter et al. (29) found substitution
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previously for the equivalent mutations in KIR2DL2. Reduced but significant levels of binding were observed for
mutants I139K, E201A, and H278A. For E201A this intermediate result matches that seen in surface plasmon
resonance experiments for the equivalent mutation in
KIR2DL2; for the other two mutations the KIR2DL2
equivalent preserved no demonstrable binding to HLACw3 (17). Of note, alanine is the naturally occurring residue at position 278 in KIR3DL2.
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Human KIR3DL1 and chimpanzee Pt-KIR3DL1/2 are
homologous MHC class I receptors of NK cells with different inhibitory specificity. Ligands for KIR3DL1 are Bw4
MHC-B allotypes; ligands for Pt-KIR3DL1/2 include
Bw4 MHC-B allotypes, a Bw6 MHC-B allotype, and
MHC-A allotypes. Previous analysis suggested that chimpanzee class I molecules are weaker inhibitors of NK cell
cytotoxicity than their human counterparts, but that chimpanzee Pt-KIR3DL1/2 is a stronger receptor for shared
Bw4 HLA-B ligands than human KIR3DL1 (22). To
study these differences we developed the SEAP assay. Like
the cytotoxicity assay it involves interaction between two
cell types but was designed to eliminate the well known
complications that can confound the interpretation of data
obtained from inhibition assays of NK cell cytotoxicity.
First, the SEAP assay limits interaction to one type of classical MHC class I molecule and one type of KIR, whereas
NK cells express multiple receptors; second, the SEAP assay measures a positive effect – secretion of AP, whereas in
the cytotoxicity assay the critical parameter is lack of killing, i.e.: no effect.
Signals generated in the SEAP assay were shown to be dependent upon interaction between MHC class I and KIR.
Major elements of the KIR3DL1 and Pt-KIR3DL1/2 MHC
class I specificity as dissected from analysis of inhibition of NK
cell cytotoxicity were reproduced in the SEAP assay. Thus,
KIR3DL1 was only stimulated by Bw4 HLA-B allotypes,
Pt-KIR3DL1/2 also reacted with the Bw6B*1502 and
within the subsets of positively reactive allotypes there was
variability in the strength of the response (as is also characteristic of cytotoxicity assays). Moreover, in the SEAP assay PtKIR3DL1/2 behaved as a stronger receptor for Bw4HLA-B
allotypes than human KIR3DL1, whereas chimpanzee MHC
class I molecules were much weaker inhibitors of both KIR
than their human counterparts.
By analysis of domain-swap, deletion, and point mutants of KIR3DL1 and Pt-KIR3DL1/2 we have demonstrated that structural difference in their D0 domains is a
major contributor to their differential avidity for MHC
class I. Specifically, a natural two amino acid deletion in
Pt-KIR3DL1/2 corresponding to residues 50 and 51 of
KIR3DL1 is responsible for its enhanced response to
Bw4 HLA-B allotypes. Deletion of these residues in
KIR3DL1 was not essential to produce enhanced response, substitution of alanine at positions 50 or 51 had
similar effect.

In this study 24 point mutations in the extracellular domains of KIR3DL1 were characterized. Mostly alanine mutations, they comprised 15 in D0, 4 in D1, and 5 in D2.
None of the mutations in D0 significantly reduced the response to Bw4 HLA-B. Conversely several mutations in
the D1 and D2 domains diminished or abrogated the response. The pattern of residues that did or did not reduce
the response in the SEAP assay correlated well with the
crystallographic structures of KIR:HLA-C complexes, suggesting that the effects are largely at the level of ligand binding. Consequently, our mutational analysis of KIR3D is
consistent with a picture in which the D1 and D2 domains
of KIR3DL1 interact with Bw4 HLA-B with orientation
similar, but not necessarily identical, to that seen in the
KIR2D:HLA-C complexes (17, 18). Within this context
the data described here indicates that the enhancing function of the KIR3DL1 D0 domain involves interaction distinct from the contact made between the D1 and D2 domains and Bw4HLA-B. Three models for this interaction
will be considered. In the first model the D0 domain makes
an additional contact with cognate Bw4 HLA-B ligand,
thereby increasing the overall strength of the individual
ligand–receptor interaction. In the second model the D0
domain contacts the Bw4 HLA-B ligand bound by the D1
and D2 domains of a different KIR3DL1 molecule. This
mode of interaction could facilitate the aggregation of
ligand–receptor complexes in the cell membranes at the
point of cell-cell contact. In the third model the D0 domain
makes contact with other KIR molecules, also facilitating
aggregation of receptors and/or receptor–ligand complexes
in the NK cell membrane. None of these models is either
eliminated or strongly favored by the data as it stands.
Whatever the mechanism the enhancing contacts made by
the D0 domain appear necessary for the function of
KIR3DL1, as also suggested by Rojo et al.’s analysis of domain-deletion mutants in which all three Ig-like domains
were needed for binding to Bw4 HLA-B (21).
Residues 49–52, that appear most important for D0 domain mediated enhancement, are predicted to form part of
the external C strand of the -pleated sheet comprising
strands A, G, F, C, and C. In considering model 1, the
homologous strands in the D1 and D2 domains of KIR2D
do not contact HLA-C in the crystallographic structures of
the complexes. One possible effect of the enhancing mutations and deletions could be to distort the CC loop, which
is important for binding of the 2 Ig domain KIR to MHC
class I. In considering the second model, a second binding
site on MHC class I has been proposed for the 2 Ig domain
KIR (30). However, in the cocrystal of KIR2DL2 with
HLA-Cw3 this interaction involves the B and E -strands
not the C strand. If KIR-KIR aggregation is required for
efficient signal transduction, then the increased MHC class
I–independent, “background” release of AP by the F50A
and H51A transfectants provides data consistent with
model 3.
Although deletion or alanine substitution within residues
49–51 of the D0 domain enhanced binding of KIR3DL1
to Bw4 HLA-B allotypes, none of these changes pro-
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positions 49 and 50 in the D0 domain increased SEAP release in response to the MHC class I–negative cell line,
721.221. This MHC class I–independent signal could have
been caused by increase in receptor-receptor aggregation,
which may have physiological significance. Indeed, a
model for KIR2D aggregation to augment signal transduction has been proposed by Snyder et al. (20) and a similar
phenomenon may occur for KIR3D.
In humans and apes (hominoids) the expressed KIR
comprise three lineages each represented in all the species
(31). Only lineage I, comprising KIR2DL4 and KIR2DL5,
is shared with the rhesus monkey, which has an additional
lineage not present in hominoids (32). Lineages II and III,
which include MHC-A and -B, and MHC-C specific KIR,
respectively, therefore appear to have originated with the
hominoids. Whereas all lineage II genes encode 3Ig KIR,
lineage III genes can encode 2Ig and 3Ig KIR and their relative numbers vary between species. Importantly, all the
2Ig KIR genes in lineage III contain a ‘pseudoexon’ encoding an unexpressed D0 domain, showing that all 2Ig KIR
in this lineage derive from ancestral genes encoding 3Ig
KIR. The mechanism underlying the lack of expression of
the pseudoexons differs amongst the genes encoding 2Ig
KIR, indicating that loss of expression of D0 is a property
that has been either selected or tolerated on multiple, independent occasions (23).
The tendency to lose the D0 domain is particularly evident in human lineage III KIR genes, all of which encode
2Ig KIR. In comparison the common chimpanzee lineage
III comprises both 2Ig and 3Ig KIR, with the latter being
in the majority (22). More specifically the KIR specific for
group C2 MHC-C allotypes is a 3Ig KIR. In contrast,
there is no evidence of any tendency for any lineage II
KIR, including those specific for MHC-A and -B, to lose
expression of the D0 domain. The data accumulated from
studying inhibition of NK cell cytotoxicity indicate that
HLA-C allotypes are more potent and more frequently
used inhibitors of NK cells than MHC-A or -B (8–10).
The distinguishing properties of the MHC-C locus suggest
it has evolved specializations that facilitate interaction of its
products with KIR, and in reciprocal fashion that may also
be true for the cognate KIR2D. Such specializations might
include strengthening direct D1 and D2 domain interaction
with MHC-C, with concomitant loss of the D0 domain
and its enhancing function. Such progression could exemplify specialization toward particular function with accompanying loss of flexibility and adaptability.
This tendency can also be seen in the lineage II KIR
where it is apparent that the human and chimpanzee KIR
have taken quite different evolutionary trajectories. In
chimpanzee this lineage is represented by a single gene
with a high frequency allele, Pt-KIR3DL1/2. This allele
encodes a receptor with broad specificity for MHC-A and
-B and has a strongly enhancing D0 domain. By contrast this
lineage is represented by two human genes, KIR3DL1 and
KIR3DL2, both of which are highly polymorphic (33). In
structure Pt-KIR3DL1/2 is a pastiche of sequence elements
present in either KIR3DL1 and KIR3DL2. In function the
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duced a positive response to Bw6 HLA-B*1502. Indeed,
of all the KIR3DL1 mutants, the only one showing a response to B*1502 was the domain swap mutant HCH in
which the D1 domain was replaced by its chimpanzee
counterpart, and its response was weak (Fig. 3). Thus, although replacement of the chimpanzee D0 domain with its
human counterpart abrogates interaction with B*1502, the
species-specific differences in the D0 domain do not account for all the differences in the specificity of KIR3DL1
and Pt-KIR3DL1/2. Substitutions in the D1 domain are
also likely to make a contribution and a role for D2 is not
ruled out.
The SEAP assay measures the product of both ligand
binding and signaling by KIR. In using chimeric KIR3D
molecules it was possible that the KIR interaction with
MHC class I would be altered in ways not relevant to the
biology. Our results indicate that is unlikely. Response in
the SEAP assay was demonstrated to be dependent upon
interaction between KIR and MHC class I. Comparison
showed that KIR exhibited similar but not identical responses in the cytotoxicity and SEAP assays. The difference
being that not all of the MHC class I allotypes which can
inhibit NK cell cytotoxicity could stimulate in the SEAP
assay and that those allotypes tended to be the weaker,
more variable inhibitors of cytotoxicity. Importantly, comparison with previous cytotoxicity experiments (12, 13, 21,
22) revealed no false positives in the SEAP assay. Lower
sensitivity in the SEAP assay could be due to reduced intensity of the signals emanating from CD3 compared with
the cytoplasmic tail of KIR3D; reduced efficiency of the
chimeric molecules to form signaling complexes within the
cell membrane; or the absence of additional NK cell receptors or coreceptors for MHC class I interaction that not are
expressed by the Jurkat T cells used in the SEAP assay. As
in cytotoxicity assays, there is interexperiment variation in
the SEAP assay data. Accordingly, experiments were designed so that important comparisons were always made
within the same experiment, and each experiment was performed on at least three occasions. Importantly, the main
conclusions of the investigation were reached by separate
analysis of three distinct types of mutant KIR: domain
swap, deletion, and point mutants.
An advantage the SEAP assay has over binding assays that
use soluble, recombinant KIR (29) is its basis on cell–cell
interaction. In addition to being more physiological all the
molecules contributing to the assay should be correctly
folded and modified by mammalian cellular machinery,
making it unlikely that nonphysiological binding sites will
engage. Thus, we were unlikely to observe false positive
reactions for mutant KIR3DL1 molecules. The configuration of the SEAP assay reduces the probability of confounding false positive reactions due to other receptor–
ligand interactions, as can occur when measuring inhibition
of NK cell cytotoxicity. That certain point mutations in
the D1 and D2 domains abrogated KIR response to MHC
class I demonstrated that the assay system is sensitive to
changes in KIR-MHC binding caused by single amino acid
substitutions. Of note in this regard, the point mutations at
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